Loading patent…
AssigneeSerono Genetics Institute S.A.
InventorsDaniel Cohen, Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Bernard Bihain, Laurent Essioux
Estimating the term…
The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.
A composition comprising an isolated and purified polypeptide comprising the amino acid sequence of SEQ ID NO:232 or an epitope-containing fragment thereof, said fragment consisting of at least 8 contiguous amino acids selected SEQ ID NO:232.
A method of making an SBG1 polypeptide, said method comprising the following steps:
An isolated polypeptide comprising SEQ ID NO:
Dependencies are inferred from the claim text.